Enovis Corporation (ENOV) - Q2 2026 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended July 3, 2026. Enovis Corporation is an innovation-driven medical technology company operating through two segments: Prevention & Recovery (P&R), providing orthopedic and recovery solutions, and Reconstructive (Recon), offering surgical implant solutions. The company is a large accelerated filer with 57.7 million shares of common stock outstanding as of July 31, 2026.
Key Financial Metrics
| Metric | Q2 2026 (3 Months) | Q2 2025 (3 Months) | YTD 2026 (6 Months) | YTD 2025 (6 Months) |
|---|---|---|---|---|
| Net Sales | $582.8 million | $564.5 million | $1,171.9 million | $1,123.4 million |
| Gross Profit | $359.2 million | $334.7 million | $724.7 million | $666.9 million |
| Gross Margin | 61.6% | 59.3% | 61.8% | 59.4% |
| Operating Income | $17.4 million | ($16.8) million | $23.9 million | ($63.6) million |
| Net Loss (GAAP) | ($1.0) million | ($36.5) million | ($9.5) million | ($92.3) million |
| Adjusted EBITDA | $104.3 million | $91.2 million | $207.9 million | $178.2 million |
| Adjusted EBITDA Margin | 17.9% | 16.2% | 17.7% | 15.9% |
| Cash & Equivalents | $12.6 million | $44.1 million | $12.6 million | $44.1 million |
| Total Debt | $1,284.5 million | $1,296.8 million | $1,284.5 million | $1,296.8 million |
Note: All figures in millions unless otherwise noted. Net Loss attributable to Enovis Corporation is reported.
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 3.2% QoQ and 4.3% YTD, driven by organic growth in existing businesses (Recon +6.3%, P&R +3.5%) and favorable foreign currency translation (+1.0% QoQ, +2.6% YTD). This was partially offset by the October 2025 divestiture of the Dr. Comfort Footcare Solutions product line.
- Profitability Improvement: The company returned to operating profitability ($17.4M) compared to a loss of $16.8M in the prior year quarter. Gross margin expanded 230 basis points QoQ due to improved product mix, tariff refunds ($4.0M benefit), and a reduction in inventory fair value step-up amortization charges.
- Expense Management: SG&A expenses decreased $3.4M QoQ, primarily due to a $12.1M reduction in strategic transaction costs (including a $5.7M gain on contingent consideration settlement) and lower acquisition integration costs. R&D expenses increased slightly due to investments in surgical productivity solutions.
- Segment Performance:
- Recon: Sales up 7.5% QoQ; Adjusted EBITDA up to $54.0M (18.3% margin).
- P&R: Sales down 0.8% QoQ due to divestiture impact; Adjusted EBITDA up to $50.3M (17.5% margin).
Guidance, Outlook, and Risks
- Liquidity: Cash and cash equivalents decreased to $12.6 million from $36.4 million at year-end 2025. The company maintains a $1.1 billion revolving credit facility with $942 million available and a $700 million term loan. Management believes liquidity is adequate for the next 12 months.
- Debt Covenants: The company is in compliance with financial covenants, maintaining a senior secured leverage ratio under 3.50:1.00 and an interest coverage ratio above 3.00:1.00.
- Strategic Initiatives: Continued integration of the Lima Acquisition and investment in R&D for computer-assisted surgery. The company revised its Adjusted EBITDA definition to exclude inventory step-up charges for consistency.
- Risks: Key risks include foreign currency fluctuations (44-45% of sales are international), supply chain disruptions, geopolitical tensions, regulatory compliance (EU MDR), and the successful integration of acquisitions. The company faces potential dilution from convertible notes if stock price exceeds the cap price of $89.72.
Investor Verification Checklist
- Cash Position: Verify the sustainability of operations with only $12.6M in cash on hand despite strong operating cash flow ($99.0M YTD).
- Divestiture Impact: Confirm the long-term revenue impact of the Dr. Comfort divestiture ($14.4M sales loss in Q2) versus the strategic benefits.
- Non-GAAP Adjustments: Review the reconciliation of Net Loss to Adjusted EBITDA, specifically the $5.7M non-cash gain on contingent consideration and the removal of inventory step-up charges.
- Tariff Exposure: Assess the sustainability of the $4.0M tariff benefit in Q2 and the net $1.7M expense YTD.
- Debt Structure: Monitor the $460M convertible notes maturing in 2028 and the associated capped call transactions.